Serum Institute of India is the vaccine producer that will invest 50 million pounds ($68.24 million) in Oxford Biomedica, one of the COVID-19 vaccine manufacturers for drug major AstraZeneca, the British cell therapy firm said.

• Nepal Signs 7 MoUs with India for Projects 
• Trump to Hit Patented Drugs with a 100% Tariff 
• Government Looking to Talk with Airlines Amid Fuel Surcharge 
• Bank of Baroda Shares Slip Despite Q4 Global Advances Jumping 16.23%
• Pharma Stocks to be in Focus on Monday as Trump Tariff Reports Rattle Drug Sector

The proceeds of the transaction will be used to fund the development of the fallow area at Oxbox, the group’s 84,000 sq. ft manufacturing facility based in Oxford, UK, into a flexible advanced manufacturing space and the validation of several independent cGMP suites, expected to come online in mid-2023.